Cipla (CIPLA) Weekly Analysis
Price & Volume
This week, the stock price saw a slight decrease of 1.45%. The trading range was 1.37%, indicating moderate price movement within the week. Average daily volume was 1,059,900 shares, a small increase of 5.27% from the previous week. The stock closed slightly below its 50-day and 200-day moving averages.
Technicals
This week, the stock closed at 1418.6, down 1.45% WoW. The 20-week Moving Average (MA) slope is up, indicating short-term upward momentum, while the 50-week MA slope is down, suggesting a weakening medium-term trend. The RSI is at 48.4, down WoW, signaling a dip in buying interest. Bollinger Band width narrowed to 6.8%, indicating lower volatility compared to recent weeks. Overall, the technical picture shows mixed signals between short-term strength and medium-term weakness.
Fundamentals
In the quarter ending March 2026, Cipla reported a revenue of ₹6,541.0 and a net profit of ₹543.0. Revenue decreased by 7.5% QoQ and 2.8% YoY, while net profit saw a sharper decline of 19.4% QoQ and 55.3% YoY. The company's operating margin was 15.0% in the recent quarter. Cipla currently trades at a Price-to-Earnings (PE) ratio of 33.3x and a Price-to-Book (PB) ratio of 3.4x.
News
During the week of July 13-17, 2026, Cipla disclosed its Crisil ESG scores as per SEBI regulations, a development noted through metadata. The broader pharmaceutical sector demonstrated strong performance, with the NSE Pharma index showing a 13.5% return year-to-date, making it a top performer. Analysts indicated a positive outlook for the pharma sector, with Bajaj Finserv AMC specifically betting on pharmaceuticals as market conditions broaden. This sector's strength was highlighted amidst a generally positive market outlook, with Mirae Asset CIO expecting index returns to slightly exceed long-term averages. Additionally, the NSE announced the upcoming launch of futures and options on the Nifty India FPI 150 Index from August 12, following SEBI approval.
Events
Cipla Limited has submitted a certificate confirming compliance with SEBI regulations regarding dematerialization of securities for the quarter ended June 30, 2026. This ensures proper handling of share certificates and updates to the register of members.
Cipla Limited has received an ESG rating of 'Crisil ESG 69' and 'Crisil Core ESG 66' from Crisil ESG Ratings & Analytics. This announcement provides shareholders with an assessment of the company's environmental, social, and governance performance.
Cipla announced its Q1FY27 unaudited financial results will be released on July 23, 2026, followed by an earnings conference call. Shareholders can expect a discussion of financial performance.
Cipla Limited has issued a corrigendum to its 90th Annual General Meeting transcript due to typographical errors. The corrected transcript has been submitted to the stock exchanges for shareholders' record.
Cipla Limited announced the transcript of its 90th Annual General Meeting held on June 25, 2026. The transcript is now available on the company's website.
Cipla Limited has received an ESG rating of 'Crisil ESG 69' and 'Crisil Core ESG 66' from Crisil ESG Ratings & Analytics. This announcement provides shareholders with an assessment of the company's environmental, social, and governance performance.
Cipla announced its Q1FY27 unaudited financial results will be released on July 23, 2026, followed by an earnings conference call. Shareholders can expect a discussion of financial performance.
Cipla Limited has issued a corrigendum to its 90th Annual General Meeting transcript due to typographical errors. The corrected transcript has been submitted to the stock exchanges for shareholders' record.
Cipla Limited announced the transcript of its 90th Annual General Meeting held on June 25, 2026. The transcript is now available on the company's website.
Weekly Snapshot
Highlights
- The stock price declined by 1.45% this week, closing at 1418.6, with trading volume increasing by 5.27%.
- Technical indicators show mixed signals, with short-term upward momentum contrasting with a declining medium-term trend and weakening momentum.
- Cipla received ESG ratings from Crisil, achieving 'Crisil ESG 69' and 'Crisil Core ESG 66'.
- The company announced its Q1FY27 earnings release date and will host an earnings call on July 23, 2026.
- The pharmaceutical sector continues to show strength, with the NSE Pharma index up 13.5% year-to-date, making it a top performer.
What This Means
Cipla experienced a slight price decline this week amidst mixed technical signals, with short-term strength but weakening medium-term trends. The company announced upcoming Q1FY27 results and received ESG ratings, while the broader pharmaceutical sector continues its strong performance. Trading volume saw a modest increase, and the stock remains near its 50-day and 200-day moving averages.
Latest Quarter Info
The latest quarterly results for the period ending March 2026 indicate a mixed signal in performance. Revenue experienced a sequential decline of 7.53% quarter-over-quarter (QoQ), while also showing a year-over-year (YoY) decrease of 2.81%. Profitability trends are also down, with net profit falling 19.44% QoQ and a more significant 55.27% YoY. The operating margin remained stable at 15.0%, suggesting cost management efforts have held steady despite revenue pressures. However, the substantial year-over-year drop in net profit and EPS, down 54.59%, warrants attention. The combination of declining revenue and profit, particularly on a YoY basis, presents a challenging operational environment.